Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013556 | 1.00 | HSD11B1 (0.59) | HSD11B1PKMNPC1MCHR1CNR2 | |
| SCHEMBL4006910 | 0.91 | HSD11B1 (0.61) | HSD11B1MCHR1CNR2LMNATSHR | |
| SCHEMBL4006904 | 0.91 | HSD11B1 (0.61) | HSD11B1MCHR1CNR2LMNATSHR | |
| SCHEMBL4009203 | 0.90 | HSD11B1 (0.68) | HSD11B1CNR2L3MBTL1ALDH1A1HTT | |
| SCHEMBL4009206 | 0.90 | HSD11B1 (0.68) | HSD11B1CNR2L3MBTL1ALDH1A1HTT | |
| SCHEMBL4006076 | 0.86 | HSD11B1 (0.63) | HSD11B1CNR2L3MBTL1HTTKMT2A | |
| SCHEMBL4006086 | 0.86 | HSD11B1 (0.63) | HSD11B1CNR2L3MBTL1HTTKMT2A | |
| SCHEMBL4002244 | 0.84 | HSD11B1 (0.63) | HSD11B1PKMCNR2LMNATSHR | |
| SCHEMBL4002241 | 0.84 | HSD11B1 (0.63) | HSD11B1PKMCNR2LMNATSHR | |
| SCHEMBL4009196 | 0.83 | HSD11B1 (0.60) | HSD11B1CNR2L3MBTL1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885PKM 1604/4885NPC1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.